Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation

Molecular Cancer, Год журнала: 2023, Номер 22(1)

Опубликована: Окт. 6, 2023

Abstract Pancreatic cancer (PC) is one of the most common malignancies. Surgical resection a potential curative approach for PC, but patients are unsuitable operations when at time diagnosis. Even with surgery, some may still experience tumour metastasis during operation or shortly after as precise prognosis evaluation not always possible. If miss opportunity surgery and resort to chemotherapy, they face challenging issue chemotherapy resistance. In recent years, liquid biopsy has shown promising prospects in disease diagnosis, treatment monitoring, assessment. As noninvasive detection method, offers advantages over traditional diagnostic procedures, such tissue biopsy, terms both cost-effectiveness convenience. The information provided by helps clinical practitioners understand molecular mechanisms underlying occurrence development, enabling formulation more personalized decisions each patient. This review introduces biomarkers methods including circulating cells (CTCs), DNA (ctDNA), noncoding RNAs (ncRNAs), extracellular vesicles (EVs) exosomes. Additionally, we summarize applications early response, resistance assessment, prognostic PC.

Язык: Английский

---

Extracellular vesicles as a promising source of lipid biomarkers for breast cancer detection in blood plasma

Journal of Extracellular Vesicles, Год журнала: 2024, Номер 13(3)

Опубликована: Март 1, 2024

Abstract Extracellular vesicles (EVs), including exosomes and microvesicles, mediate intercellular communication in cancer, from development to metastasis. EV‐based liquid biopsy is a promising strategy for cancer diagnosis as EVs can be found patients’ body fluids. In this study, the lipid composition of breast cancer‐derived was studied well potential blood plasma identification biomarkers detection. Initially, an untargeted lipidomic analysis carried out panel cancerous non‐cancerous mammary epithelial cells their secreted EVs. We that are enriched sphingolipids glycerophospholipids compared parental cells. The initial vitro study showed correctly classified (100% accuracy) between non‐cancerous, into respective subtypes, based on composition. Subsequently, women diagnosed with (primary or progressive metastatic cancer) healthy women. Correspondingly, when were analysed, patients overall accuracy 93.1%, EVs’ Similarly, primary 95% correct classification. Furthermore, cancers 89.5%. This reveals lipids may source detection cancer. Additionally, demonstrates usefulness lipidomics EV EV‐associated biomarker discovery studies. proof‐of‐concept starting point further

Язык: Английский

---

Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine

Cancer Science, Год журнала: 2024, Номер 115(4), С. 1060 - 1072

Опубликована: Фев. 3, 2024

Abstract Liquid biopsy is emerging as a pivotal tool in precision oncology, offering noninvasive and comprehensive approach to cancer diagnostics management. By harnessing biofluids such blood, urine, saliva, cerebrospinal fluid, pleural effusions, this technique profiles key biomarkers including circulating tumor DNA, cells, microRNAs, extracellular vesicles. This review discusses the extended scope of liquid biopsy, highlighting its indispensable role enhancing patient outcomes through early detection, continuous monitoring, tailored therapy. While advantages are notable, we also address challenges, emphasizing necessity for precision, cost‐effectiveness, standardized methodologies broader application. The future trajectory set expand reach personalized medicine, fueled by technological advancements collaborative research.

Язык: Английский

---

The Circulating Biomarkers League: Combining miRNAs with Cell-Free DNAs and Proteins

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(6), С. 3403 - 3403

Опубликована: Март 17, 2024

The potential of liquid biopsy for the prognosis and diagnosis diseases is unquestionable. Within evolving landscape disease diagnostics personalized medicine, circulating microRNAs (c-miRNAs) stand out among biomarkers found in blood circulation other biological fluids due to their stability, specificity, non-invasive detection biofluids. However, complexity human limitations inherent single-marker highlight need a more integrative approach. It has been recently suggested that multi-analyte approach offers advantages over single-analyte diseases. In this review, we explore combining three well-studied classes biofluids—miRNAs, DNAs, proteins—to enhance accuracy efficacy monitoring. Initially, provide an overview each biomarker class discuss main disadvantages highlighting superiority c-miRNAs biomarkers. Additionally, challenges future directions integrating these into clinical practice, emphasizing standardized protocols further validation studies. This integrated revolutionize precision medicine by offering insights mechanisms, facilitating early detection, guiding therapeutic strategies. collaborative power with represents promising frontier comprehensive understanding management complex Nevertheless, several must be addressed before can translated practice.

Язык: Английский

---

Liquid Biopsy: An Evolving Paradigm for Non-invasive Disease Diagnosis and Monitoring in Medicine

Cureus, Год журнала: 2023, Номер unknown

Опубликована: Дек. 8, 2023

Liquid biopsy stands as an innovative instrument in the realm of precision medicine, enabling non-invasive disease diagnosis and early detection cancer. helps extraction circulating tumor DNA (ctDNA), cells (CTCs), cell-free (cfDNA) from blood samples other body fluids, thereby facilitating prediction high-risk patients. Various techniques such advanced sequencing methods biomarker-based cell capture have led to isolation study different biomarkers ctDNA, cfDNA, CTCs. These biopsies also immense potential various diseases across all medical specialties, screening cases, immune response patterns infectious diseases, help predicting treatment outcomes. Although liquid has disrupt field diagnosis, it is met by challenges limited tumor-derived components, less specificity, inadequate advancement isolate biomarkers. Despite these challenges, provide become a minimally invasive method that would facilitate real-time monitoring patients, which differentiates them traditional tissue biopsies. This article aims complete overview current technologies, biomarkers, fluids can be used its clinical applications impact holds prompt management cancers.

Язык: Английский

---

Point‐Of‐Care Ultra‐Portable Single‐Molecule Bioassays for One‐Health

Advanced Materials, Год журнала: 2023, Номер 36(13)

Опубликована: Дек. 18, 2023

Abstract Screening asymptomatic organisms (humans, animals, plants) with a high‐diagnostic accuracy using point‐of‐care‐testing (POCT) technologies, though still visionary holds great potential. Convenient surveillance requires easy‐to‐use, cost‐effective, ultra‐portable but highly reliable, in‐vitro‐diagnostic devices that are ready for use wherever they needed. Currently, there not yet such available on the market, couple more promising technologies developed at readiness‐level 5: Clustered‐Regularly‐Interspaced‐Short‐Palindromic‐Repeats (CRISPR) lateral‐flow‐strip tests and Single‐Molecule‐with‐a‐large‐Transistor (SiMoT) bioelectronic palmar devices. They both hold key features delineated by World‐Health‐Organization POCT systems an occurrence of false‐positive false‐negative errors <1–5% resulting in diagnostic‐selectivity sensitivity >95–99%, while limit‐of‐detections few markers. CRISPR‐strip is molecular assay that, can detect down to copies DNA/RNA markers blood SiMoT immunometric test single oligonucleotide, protein marker, or pathogens 0.1mL blood, saliva, olive‐sap. These prospectively enable systematic reliable ones prior worsening/proliferation illnesses allowing timely diagnosis swift prognosis. This could establish proactive healthcare ecosystem results effective treatments all living generating diffuse well‐being efficient costs.

Язык: Английский

---

Liquid Biopsy in the Clinical Management of Cancers

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(16), С. 8594 - 8594

Опубликована: Авг. 6, 2024

Liquid biopsy, a noninvasive diagnosis that examines circulating tumor components in body fluids, is increasingly used cancer management. An overview of relevant literature emphasizes the current state liquid biopsy applications care. Biomarkers particularly DNA (ctDNA), RNAs (ctRNA), cells (CTCs), extracellular vesicles (EVs), and other components, offer promising opportunities for early diagnosis, treatment selection, monitoring, disease assessment. The implementation precision medicine has shown significant potential various types, including lung cancer, colorectal breast prostate cancer. Advances genomic molecular technologies such as next-generation sequencing (NGS) digital polymerase chain reaction (dPCR) have expanded utility enabling detection somatic variants actionable alterations tumors. also demonstrated predicting responses, monitoring minimal residual (MRD), assessing heterogeneity. Nevertheless, standardizing techniques, interpreting results, integrating them into clinical routine remain challenges. Despite these challenges, implications management, offering dynamic approach to understanding biology guiding personalized strategies.

Язык: Английский

---

Circulating Cell-Free DNA Integrity for Breast and Prostate Cancer: What Is the Landscape for Clinical Management of the Most Common Cancers in Women and Men?

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(3), С. 900 - 900

Опубликована: Янв. 22, 2025

Breast cancer (BC) and prostate (PCa) are major health problems for women men worldwide. Although therapeutic approaches have increased, the complexity associated with their heterogeneity progression requires better ways to monitor them over time. Cell-free DNA integrity (cfDI) represents a viable alternative needle biopsy has potential be representative of at all stages. In addition advantages liquid in terms cost reduced invasiveness, cfDI can used detect repetitive elements (e.g., ALU LINE1), which could circumvent problem mutational BC PCa. this review, we summarise latest findings on studies The results show that improve early detection, metastasis, recurrence BC, while limited prevent its clinical value PCa from being fully defined. However, it is expected further near future will help introduce use as another biomarker monitoring patients.

Язык: Английский

---

Innovative laboratory techniques shaping cancer diagnosis and treatment in developing countries

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Фев. 8, 2025

Abstract Cancer is a major global health challenge, with approximately 19.3 million new cases and 10 deaths estimated by 2020. Laboratory advancements in cancer detection have transformed diagnostic capabilities, particularly through the use of biomarkers that play crucial roles risk assessment, therapy selection, disease monitoring. Tumor histology, single-cell technology, flow cytometry, molecular imaging, liquid biopsy, immunoassays, diagnostics emerged as pivotal tools for detection. The integration artificial intelligence, deep learning convolutional neural networks, has enhanced accuracy data analysis capabilities. However, developing countries face significant challenges including financial constraints, inadequate healthcare infrastructure, limited access to advanced technologies. impact COVID-19 further complicated management resource-limited settings. Future research should focus on precision medicine early diagnosis sophisticated laboratory techniques improve prognosis outcomes. This review examines evolving landscape detection, focusing breakthroughs limitations countries, while providing recommendations advancing tumor resource-constrained environments.

Язык: Английский

---

Circulating Tumor Cells and DNA in Early Diagnosis and Prognosis of Metastatic Cancer

IntechOpen eBooks, Год журнала: 2025, Номер unknown

Опубликована: Фев. 27, 2025

Metastatic cancer remains a major challenge in oncology, often diagnosed late with limited intervention options. This chapter highlights the role of circulating tumor cells (CTCs) and DNA (ctDNA) as biomarkers for early detection, diagnosis, prognosis. Liquid biopsy, non-invasive method, analyzes blood components like CTCs, which provide insights into heterogeneity metastatic potential, ctDNA, reflects genetic mutations burden. These enable real-time monitoring, aiding understanding progression, treatment response, residual disease, resistance mechanisms. Advances detection methods emphasize their clinical relevance personalized treatment. Integrating CTCs ctDNA oncology could revolutionize management through individualized strategies, enhancing outcomes. The concludes challenges future directions implementing these precision oncology.

Язык: Английский

---